Genmab | GEN - Nettoeinkommen

Aktienkurs
1,637.00
Täglich Wechseln
-8.00 -0.49%
Monatlich
-10.67%
Jährlich
20.06%
Q1 Prognose
1,614.31




Nettoeinkommen Veränderung Datum
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Almirall EUR 19.58M 7M 2025-12
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.33B 1.88B 2025-12
argenx SE USD 532.95M 188.69M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Bayer EUR -3.76B 2.79B 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Demant DKK 427M 690M 2025-12
Exelixis USD 193.58M 8.73M 2025-09
Fresenius Medical Care EUR 327M 52.2M 2025-12
Galapagos EUR 782.15M 984.26M 2025-12
Genmab DKK 31M 370M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
GN Store Nord DKK 344M 271M 2025-12
GRIFOLS EUR 98.25M 28.72M 2025-12
Hikma Pharmaceutical USD 164M 45M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Lonza CHF 426M 119M 2025-06
Merck EUR 319M 583M 2025-12
Novartis USD 2.41B 1.52B 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR -801M 3.6B 2025-12
UCB EUR 1.08B 608M 2025-12